Best Practice & Research Clinical Haematology
Volume 19, Issue 3 , Pages 495-517 , September 2006

Myelofibrosis with myeloid metaplasia: Disease overview and non-transplant treatment options

  • Ruben A. Mesa (Associate Professor of Medicine)

      Affiliations

    • Corresponding Author InformationCorresponding author
  • John T. Reilly (Consultant Haematologist and Honorary Reader in Haematology)

References 

  1. Heuck G. Zwei falle von Leukamie mit eigenthumlichem blut-resp knochenmarksbefund. Archives of Pathology and Physiology Klinische Medicine. 1879;78:475–496
  2. Jackson H, Lemon H. Agnogenic myeloid metaplasia of the spleen: a syndrome simulating other more definite hematologic disorders. New England Journal of Medicine. 1940;222:985–994
  3. Tefferi A. Myelofibrosis with myeloid metaplasia. New England Journal of Medicine. 2000;342:1255–1265
  4. Hirsch E. Generalized osteosclerosis with chronic polycythemia vera. Archives of Pathology. 1935;19:91–97
  5. Mesa RA, Silverstein MN, Jacobsen SJ, et al. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976–1995. American Journal of Hematology. 1999;61:10–15
  6. Kutti J, Ridell B. Epidemiology of the myeloproliferative disorders: essential thrombocythaemia, polycythaemia vera and idiopathic myelofibrosis. Pathologie Biologie (Paris). 2001;49:164–166
  7. Dupriez B, Morel P, Demory J, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system [see comments]. Blood. 1996;88:1013–1018
  8. Anderson RE, Hoshino T, Yamamoto T. Myelofibrosis with myeloid metaplasia in survivors of the atomic bomb in Hiroshima. Annals of Internal Medicine. 1964;60:1–18
  9. Johnson S, Bateman C, Beard M, et al. Long-term haematologic complications of thorotrast. Quarterly Journal of Medicine. 1977;46:259–271
  10. Tsukamoto N, Morita K, Maehara T, et al. Clonality in chronic myeloproliferative disorders defined by X-chromosome linked probes: demonstration of heterogeneity in lineage involvement [see comments]. British Journal of Haematology. 1994;86:253–258
  11. Ruutu T, Partanen S, Knuutila S. Clonal karyotype abnormalities in erythroid and granulocyte-monocyte precursors in polycythaemia vera and myelofibrosis. Scandinavian Journal of Haematology. 1983;31:253–256
  12. Buschle M, Janssen JW, Drexler H, et al. Evidence for pluripotent stem cell origin of idiopathic myelofibrosis: clonal analysis of a case characterized by a N-ras gene mutation. Leukemia. 1988;2:658–660
  13. Reeder TL, Bailey RJ, Dewald GW, Tefferi A. Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia. Blood. 2003;101:1981–1983
  14. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–1061
  15. Levine RL, Wadleigh M, Cools J. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myelofibrosis with myeloid metaplasia. Cancer Cell. 2005;
  16. Mesa RA, Hanson CA, Rajkumar SV, et al. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood. 2000;96:3374–3380
  17. Castro-Malaspina H, Rabellino JA, Yen A, et al. Human megakaryocyte stimulation of proliferation of bone marrow fibroblasts. Blood. 1981;57:781–787
  18. Martyre MC, Le Bousse-Kerdiles MC, Romquin N, et al. Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis [see comments]. British Journal of Haematology. 1997;97:441–448
  19. Rameshwar P, Denny TN, Stein D, Gascon P. Monocyte adhesion in patients with bone marrow fibrosis is required for the production of fibrogenic cytokines. Potential role for interleukin-1 and TGF-beta. Journal of Immunology. 1994;153:2819–2830
  20. Vannucchi AM, Bianchi L, Cellai C, et al. Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low) mice) [see comment]. Blood. 2002;100:1123–1132
  21. Ohneda K, Yamamoto M. Roles of hematopoietic transcription factors GATA-1 and GATA-2 in the development of red blood cell lineage. Acta Haematology. 2002;108:237–245
  22. Shivdasani RA, Fujiwara Y, McDevitt MA, Orkin SH. A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. European Molecular Biology Organization Journal. 1997;16:3965–3973
  23. Chagraoui H, Komura E, Tulliez M, et al. Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood. 2002;100:3495–3503
  24. Vannucchi AM, Bianchi L, Paoletti F, et al. A patho-biological pathway linking thrombopoietin, GATA-1 and TGF-{beta}1 in the development of myelofibrosis. Blood. 2005;
  25. Centurione L, Di Baldassarre A, Zingariello M, et al. Increased and pathologic emperipolesis of neutrophils within megakaryocytes associated with marrow fibrosis in GATA-1(low) mice. Blood. 2004;104:3573–3580
  26. Cervantes F, Pereira A, Marti JM, et al. Bone marrow lymphoid nodules in myeloproliferative disorders: association with the nonmyelosclerotic phases of idiopathic myelofibrosis and immunological significance. British Journal of Haematology. 1988;70:279–282
  27. Gordon BR, Coleman M, Kohen P, Day NK. Immunologic abnormalities in myelofibrosis with activation of the complement system. Blood. 1981;58:904–910
  28. Cappio FC, Vigliani R, Novarino A, et al. Idiopathic myelofibrosis: a possible role for immune-complexes in the pathogenesis of bone marrow fibrosis. British Journal of Haematology. 1981;49:17–21
  29. Mesa RA, Steensma DP, Pardanani A, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood. 2003;101:2534–2541
  30. Mesa RA, Li CY, Schroeder G, Tefferi A. Clinical correlates of splenic histopathology and splenic karyotype in myelofibrosis with myeloid metaplasia. Blood. 2001;97:3665–3667
  31. Tefferi A, Mesa RA, Nagorney DM, et al. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood. 2000;95:2226–2233
  32. Dingli D, Utz JP, Krowka MJ, et al. Unexplained pulmonary hypertension in chronic myeloproliferative disorders. Chest. 2001;120:801–808
  33. Koch CA, Li CY, Mesa RA, Tefferi A. Nonhepatosplenic extramedullary hematopoiesis: associated diseases, pathology, clinical course, and treatment. Mayo Clinic Proceedings. 2003;78:1223–1233
  34. Tefferi A, Elliot MA. Serious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasia. Blood. 2000;96:4007
  35. Zhang B, Lewis SM. The splenomegaly of myeloproliferative and lymphoproliferative disorders: splenic cellularity and vascularity. European Journal of Haematology. 1989;43:63–66
  36. Wilkins BS, Green A, Wild AE, Jones DB. Extramedullary haemopoiesis in fetal and adult human spleen: a quantitative immunohistological study. Histopathology. 1994;24:241–247
  37. Calhoun DA, Li Y, Braylan RC, Christensen RD. Assessment of the contribution of the spleen to granulocytopoiesis and erythropoiesis of the mid-gestation human fetus. Early Human Development. 1996;46:217–227
  38. Thiele J, Klein H, Falk S, et al. Splenic megakaryocytopoiesis in primary (idiopathic) osteomyelofibrosis. An immunohistological and morphometric study with comparison of corresponding bone marrow features. Acta Haematologica. 1992;87:176–180
  39. Douay L, Laporte JP, Lefrancois G, et al. Blood and spleen haematopoiesis in patients with myelofibrosis. Leukemia Research. 1987;11:725–730
  40. Barosi G, Ambrosetti A, Finelli C, et al. The Italian consensus conference on diagnostic criteria for myelofibrosis with myeloid metaplasia. British Journal of Haematology. 1999;104:730–737
  41. Guermazi A, Miaux Y, Chiras J. Imaging of spinal cord compression due to thoracic extramedullary haematopoiesis in myelofibrosis. Neuroradiology. 1997;39:733–736
  42. Steensma DP, Hook CC, Stafford SL, Tefferi A. Low-dose, single-fraction, whole-lung radiotherapy for pulmonary hypertension associated with myelofibrosis with myeloid metaplasia. British Journal of Haematology. 2002;118:813–816
  43. Okamura T, Kinukawa N, Niho Y, Mizoguchi H. Primary chronic myelofibrosis: clinical and prognostic evaluation in 336 Japanese patients. International Journal of Hematology. 2001;73:194–198
  44. Cervantes F, Barosi G, Demory JL, et al. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. British Journal of Haematology. 1998;102:684–690
  45. Barosi G, Viarengo G, Pecci A, et al. Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia. Blood. 2001;98:3249–3255
  46. Arora B, Sirhan S, Hoyer JD, et al. Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: a prospective evaluation of prognostic value in 94 patients. British Journal of Haematology. 2005;128:42–48
  47. Tefferi A, Mesa RA, Schroeder G, et al. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. British Journal of Haematology. 2001;113:763–771
  48. Guardiola P, Esperou H, Cazalshatem D, et al. Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia. British Journal of Haematology. 1997;98:1004–1009
  49. Deeg HJ, Gooley TA, Flowers ME, et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood. 2003;102:3912–3918
  50. Devine SM, Hoffman R, Verma A, et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood. 2002;99:2255–2258
  51. Rondelli D, Barosi G, Bacigalupo A, et al. Allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in intermediate or high risk patients with myelofibrosis with myeloid metaplasia. Blood. 2005;
  52. Kroger N, Zabelina T, Schieder H, et al. Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. British Journal of Haematology. 2005;[Published On-Line]
  53. Rodriguez JN, Martino ML, Dieguez JC, Prados D. rHuEpo for the treatment of anemia in myelofibrosis with myeloid metaplasia. Experience in 6 patients and meta-analytical approach. Haematologica. 1998;83:616–621
  54. Cervantes F, Alvarez-Larran A, Hernandez-Boluda JC, et al. Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. British Journal of Haematology. 2004;127:399–403
  55. Cervantes F, Hernandez-Boluda JC, Alvarez A, et al. Danazol treatment of idiopathic myelofibrosis with severe anemia. Haematologica. 2000;85:595–599
  56. Besa E, Nowell P, Geller N, Gardner F. Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: the value of chromosomal studies in prediciting response and survival. Cancer. 1982;49:308
  57. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proceedings of the National Academy of Sciences of the United States of America. 1994;91:4082–4085
  58. Barosi G, Grossi A, Comotti B, et al. Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. British Journal of Haematology. 2001;114:78–83
  59. Canepa L, Ballerini F, Varaldo R, et al. Thalidomide in agnogenic and secondary myelofibrosis. British Journal of Haematology. 2001;115:313–315
  60. Elliott MA, Mesa RA, Li CY, et al. Thalidomide treatment in myelofibrosis with myeloid metaplasia. British Journal of Haematology. 2002;117:288–296
  61. Grossi A, Gavazzi S, Biscardi M, et al. Thalidomide therapy effects on angiogenic growth factors (VEGF, TGF-beta) and KDR expression in myeloid metaplasia with myelofibrosis. Blood. 2002;100:a4939
  62. Marchetti M, Barosi G, Balestri F, et al. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial. Journal of Clinical Oncology. 2004;22:424–431
  63. Merup M, Kutti J, Birgergard G, et al. Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia. Medical Oncology. 2002;19:79–86
  64. Piccaluga PP, Visani G, Pileri SA, et al. Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study. Leukemia. 2002;16:1609–1614
  65. Pozzato G, Zorat F, Nascimben F, et al. Thalidomide therapy in compensated and decompensated myelofibrosis with myeloid metaplasia. Haematologica. 2001;86:772–773
  66. Strupp C, Germing U, Scherer A, et al. Thalidomide for the treatment of idiopathic myelofibrosis. European Journal of Haematology. 2004;72:52–57
  67. Tefferi A, Elliott MA. Serious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasia. Blood. 2000;96:4007
  68. Kyrtsonis MC, Kokoris SI, Kontopidou FN, et al. Development of a myeloproliferative disorder in a patient with monoclonal gammopathy of undetermined significance secreting immunoglobulin of the M class and treated with thalidomide and anti-CD20 monoclonal antibody. Blood. 2001;97:2527–2528
  69. Mesa RA, Elliott MA, Faoro L, Tefferi A. Durable and unmaintained remissions with thalidomide-based drug therapy in myelofibrosis with myeloid metaplasia: long term outcome analysis of 2 prospective trials. Blood. 2003;102:a104
  70. Battegay EJ, Raines EW, Colbert T, Ross R. TNF-alpha stimulation of fibroblast proliferation. Dependence on platelet-derived growth factor (PDGF) secretion and alteration of PDGF receptor expression. Journal of Immunology. 1995;154:6040–6047
  71. Rusten LS, Jacobsen SE. Tumor necrosis factor (TNF)-alpha directly inhibits human erythropoiesis in vitro: role of p55 and p75 TNF receptors. Blood. 1995;85:989–996
  72. Dinarello CA, Cannon JG, Wolff SM, et al. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. Journal of Experimental Medicine. 1986;163:1433–1450
  73. Steensma DP, Mesa RA, Li CY, et al. Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study. Blood. 2002;99:2252–2254
  74. Lofvenberg E, Wahlin A. Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. European Journal of Haematology. 1988;41:375–381
  75. Best PJ, Daoud MS, Pittelkow MR, Petitt RM. Hydroxyurea-induced leg ulceration in 14 patients [see comments]. Annals of Internal Medicine. 1998;128:29–32
  76. Manoharan A, Pitney WR. Chemotherapy resolves symptoms and reverses marrow fibrosis in myelofibrosis. Scandinavian Journal of Haematology. 1984;33:453–459
  77. Petti MC, Latagliata R, Spadea T, et al. Melphalan treatment in patients with myelofibrosis with myeloid metaplasia. British Journal of Haematology. 2002;116:576–581
  78. Tefferi A, Silverstein MN, Li CY. 2-Chlorodeoxyadenosine treatment after splenectomy in patients who have myelofibrosis with myeloid metaplasia. British Journal of Haematology. 1997;99:352–357
  79. Faoro LN, Tefferi A, Mesa RA. Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia. European Journal of Haematology. 2005;74:117–120
  80. Dinney CP, Bielenberg DR, Perrotte P, et al. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Research. 1998;58:808–814
  81. Tefferi A, Elliot MA, Yoon SY, et al. Clinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia. Blood. 2001;97:1896
  82. Gilbert HS. Long term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy. Cancer. 1998;83:1205–1213
  83. Mesa RA, Camoriano JK, Geyer SM, et al. A phase 2 consortium (P2C) trial of R115777 (Tipifarnib) in myelofibrosis with myeloid metaplasia. Blood. 2004;104:a1509
  84. Giles FJ, List AF, Roboz GJ, et al. Phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral VEGF-receptor inhibitor, in patients with myelofibrosis with myeloid metaplasia. Blood. 2003;102:a3431
  85. Cortes J, Giles F, O'Brien S, et al. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer. 2003;97:2760–2766
  86. Hasselbalch HC, Bjerrum OW, Jensen BA, et al. Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis. American Journal of Hematology. 2003;74:238–242
  87. Tefferi A, Mesa RA, Gray LA, et al. Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia. Blood. 2002;99:3854–3856
  88. Mesa RA, Tefferi A, Elliott MA, et al. A phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasia. British Journal of Haematology. 2001;114:111–113
  89. Hickling RA. Splenectomy in myeloid metaplasia. Quarterly Journal of Medicine. 1937;30:253
  90. Jensen M. Splenectomy in myelofibrosis. Acta Medica Scandinavica. 1964;175:533–544
  91. Jacobs P. Splenectomy and myelofibrosis. South African Medical Journal. 1976;50:550–551
  92. Silverstein MN. The evolution into and the treatment of late stage polycythemia vera. Seminars in Hematology. 1976;13:79–84
  93. Chaimoff C, Amir J, De Vries A. Splenectomy in myelofibrosis and myeloid metaplasia. Harefuah. 1974;87:211–212
  94. Silverstein MN, ReMine WH. Sex, splenectomy, and myeloid metaplasia. Journal of the American Medical Association. 1974;227:424–426
  95. Dechavanne M, Viala JJ, Barbier Y, Revol L. Indications for splenectomy in the anemic forms of myelofibrosis with myeloid metaplasia of the spleen. Semaine des Hopitaux. 1972;48:1187–1192
  96. Morgenstern L. Splenectomy for massive splenomegaly due to myeloid metaplasia. American Journal of Surgery. 1971;122:288–293
  97. Schwartz SI, Bernard RP, Adams JT, Bauman AW. Splenectomy for hematologic disorders. Archives of Surgery. 1970;101:338–347
  98. Gomes MR, Silverstein MN, Remine WH. Splenectomy for agnogenic myeloid metaplasia. Surgery, Gynecology & Obstetrics. 1967;125:106–108
  99. Morgenstern L, Kahn FH, Weinstein IM. Subtotal splenectomy in myelofibrosis. Surgery. 1966;60:336–339
  100. Mulder H, Steenbergen J, Haanen C. Clinical course and survival after elective splenectomy in 19 patients with primary myelofibrosis. British Journal of Haematology. 1977;35:419–427
  101. Cabot EB, Brennan MF, Rosenthal DS, Wilson RE. Splenectomy in myeloid metaplasia. Annals of Surgery. 1978;187:24–30
  102. Benbassat J, Penchas S, Ligumski M. Splenectomy in patients with agnogenic myeloid metaplasia: an analysis of 321 published cases. British Journal of Haematology. 1979;42:207–214
  103. Silverstein MN, ReMine WH. Splenectomy in myeloid metaplasia. Blood. 1979;53:515–518
  104. McBrine PA, Miller A, Zimelman AP, Koff RS. Polycythemia vera with myelofibrosis and myeloid metaplasia. Acute hepatic failure following splenectomy. American Journal of Clinical Pathology. 1980;74:693–696
  105. Benbassat J, Penchas S. Sex and splenectomy in agnogenic myeloid metaplasia. Acta Haematologica. 1980;64:114–116
  106. Benbassat J, Penchas S. Early splenectomy and survival in agnogenic myeloid metaplasia. An analysis of 338 cases published since 1940. Acta Haematologica. 1981;65:189–192
  107. Schwartz SI. Splenectomy for hematologic disease. Surgical Clinics of North America. 1981;61:117–125
  108. Coon WW, Liepman MK. Splenectomy for agnogenic myeloid metaplasia. Surgery, Gynecology & Obstetrics. 1982;154:561–563
  109. Jarvinen H, Kivilaakso E, Ikkala E, et al. Splenectomy for myelofibrosis. Annals of Clinical Research. 1982;14:66–71
  110. Yonemitsu H, Okuda K, Shigeta H, Kondo Y. Splenectomy in primary myelofibrosis: two long-term survivors after splenectomy. Nippon Ketsueki Gakkai Zasshi—ematologica Japonica. 1984;47:80–88
  111. Kesteven PJ, Pullan JM, Glass UH, Wetherley-Mein G. Hypersplenism and splenectomy in lymphoproliferative and myeloproliferative disorders. Clinical and Laboratory Haematology. 1985;7:297–306
  112. Aviram M, Carter A, Tatarsky I, et al. Increased platelet aggregation following splenectomy in patients with myeloproliferative disease. Israel Journal of Medical Sciences. 1985;21:415–417
  113. Wilson RE, Rosenthal DS, Moloney WC, Osteen RT. Splenectomy for myeloproliferative disorders. World Journal of Surgery. 1985;9:431–436
  114. Partanen S, Ruutu T, Juvonen E, Pantzar P. Effect of splenectomy on circulating haematopoietic progenitors in myelofibrosis. Scandinavian Journal of Haematology. 1986;37:87–90
  115. Malmaeus J, Akre T, Adami HO, Hagberg H. Early postoperative course following elective splenectomy in haematological diseases: a high complication rate in patients with myeloproliferative disorders. British Journal of Surgery. 1986;73:720–723
  116. Brenner B, Nagler A, Tatarsky I, Hashmonai M. Splenectomy in agnogenic myeloid metaplasia and postpolycythemic myeloid metaplasia. A study of 34 cases. Archives of Internal Medicine. 1988;148:2501–2505
  117. Coon WW. Splenectomy for thrombocytopenia due to secondary hypersplenism. Archives of Surgery. 1988;123:369–371
  118. Benbassat J, Gilon D, Penchas S. The choice between splenectomy and medical treatment in patients with advanced agnogenic myeloid metaplasia. American Journal of Hematology. 1990;33:128–135
  119. Lopez-Guillermo A, Cervantes F, Bruguera M, et al. Liver dysfunction following splenectomy in idiopathic myelofibrosis: a study of 10 patients. Acta Haematologica. 1991;85:184–188
  120. Mesa RA, Schwager S, Nagorney DS, Tefferi A. Palliative splenectomy for myelofibrosis with myeloid metaplasia: three decades of experience in 314 patients. Blood. 2004;104:a1510
  121. Lee WC, Lin HC, Tsay SH, et al. Esophageal variceal ligation for esophageal variceal hemorrhage in a patient with portal and primary pulmonary hypertension complicating myelofibrosis. Digestive Diseases & Sciences. 2001;46:915–919
  122. Tefferi A, Barrett SM, Silverstein MN, Nagorney DM. Outcome of portal-systemic shunt surgery for portal hypertension associated with intrahepatic obstruction in patients with agnogenic myeloid metaplasia. American Journal of Hematology. 1994;46:325–328
  123. Angermayr B, Cejna M, Schoder M, et al. Transjugular intrahepatic portosystemic shunt for treatment of portal hypertesnion due to extramedullary hematopoiesis in idiopathic myelofibrosis. Blood. 2002;99:4246
  124. Belohlavek J, Schwarz J, Jirasek A, et al. Idiopathic myelofibrosis complicated by portal hypertension treated with a transjugular intrahepatic portosystemic shunt (TIPS). Wiener Klinische Wochenschrift. 2001;113:208–211
  125. Elliott MA, Chen MG, Silverstein MN, Tefferi A. Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. British Journal of Haematology. 1998;103:505–511
  126. McFarland JT, Kuzma C, Millard FE, Johnstone PA. Palliative irradiation of the spleen. American Journal of Clinical Oncology. 2003;26:178–183
  127. Tefferi A, Jimenez T, Gray LA, et al. Radiation therapy for symptomatic hepatomegaly in myelofibrosis with myeloid metaplasia. European Journal of Haematology. 2001;66:37–42
  128. Price F, Bell H. Spinal cord compression due to extramedullary hematopoiesis. Successful treatment in a patient with long-standing myelofibrosis. Journal of the American Medical Association. 1985;253:2876–2877
  129. De Klippel N, Dehou MF, Bourgain C, et al. Progressive paraparesis due to thoracic extramedullary hematopoiesis in myelofibrosis. Case report. Journal of Neurosurgery. 1993;79:125–127
  130. Cervantes F, Tassies D, Salgado C, et al. Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. Acta Haematologica. 1991;85:124–127
  131. Mesa RA, Li CY, Ketterling RP, et al. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood. 2005;105:973–977
  132. Barosi G, Elliot MA, Canepa L, et al. Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies. Leukemia and Lymphoma. 2002;43:2301–2307
  133. Visani G, Mele A, Malagola M, et al. Sequential combination of thalidomide and erythropoietin determies transfusion independence and disease control in idiopathic myelofibrosis previously insensitive to both drugs as single agents. Leukemia. 2003;17:1669
  134. Lofvenberg E, Wahlin A. Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. European Journal of Haematology. 1988;41:375–381
  135. Mesa RA, Camoriano JK, Geyer SM, et al. A phase 2 consortium (P2C) trial of R115777 (Zarnestra) in myelofibrosis with myeloid metaplasia: interim analysis of 18 patients. Blood. 2003;102:a3428
  136. Najean Y, Rain JD. Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group. Blood. 1997;89:2319–2327
  137. Bukh H, With TK. Splenectomy in chronic non-leukemic myeloid splenomegaly with a report of osteosclerosis. Acta Chirugica Scandinavica. 1945;92:507–532
  138. Green TW, Conley C, Ashburn LI, Peters HR. Splenectomy for myeloid metaplasia of the spleen. New England Journal of Medicine. 1953;248:211–219
  139. Videbaek A. Fibrosis and sclerosis of the bone marrow. Acta Haematologica. 1956;15:235–245
  140. Milner GR, Geary CG, Wadsworth LD, Doss A. Erythrokinetic studies as a guide to the value of splenectomy in primary myeloid metaplasia. British Journal of Haematology. 1973;25:467–484
  141. Gale D, Sacks P, Lynch S, et al. The place of splenectomy in haematological disorders. South African Medical Journal. 1974;48:1240–1245
  142. Little JM. A prospective study of 100 splenectomies. Australian and New Zealand Journal of Surgery. 1978;48:390–397
  143. Benbassat JPS, Ligumski M. Splenectomy in patients with agnogenic myeloid metaplasia: an analysis of 321 published cases. British Journal of Haematology. 1979;42:207–214
  144. Musser G, Lazar G, Hocking W, Busuttl W. Splenectomy for hematologic disease. Annals of surgery. 1984;200:40–45
  145. Sharp P, Grace CS, Rozenberg MC, Ham JM. Splenectomy for massive splenomegaly. Australian and New Zealand Journal of Surgery. 1985;55:489–492
  146. Dotevall A, Kutti J, Wadenvik H, Westin J. A retrospective analysis of a consecutive series of patients splenectomized for various hematologic disorders. Acta Haematologica. 1987;77:38–44
  147. Schmitz N, Suttorp M, Schlegelberger B, et al. The role of the spleen after bone marrow transplantation for primary myelofibrosis. British Journal of Haematology. 1992;81:616–618
  148. Barosi G, Ambrosetti A, Buratti A, et al. Splenectomy for patients with myelofibrosis with myeloid metaplasia: pretreatment variables and outcome prediction. Leukemia. 1993;7:200–206
  149. Lafaye F, Rain JD, Clot P, Najean Y. Risks and benefits of splenectomy in myelofibrosis: an analysis of 39 cases. Nouvelle Revue Francaise d Hematologie. 1994;36:359–362
  150. Jameson JS, Thomas WM, Dawson S. Splenectomy for haematologic disease. Journal of Royal College of Surgery. 1996;41:307–311
  151. Mittelman MKS, Zeidman A. Splenectomy for hematologic disease—a single institution experience. Haematologica. 1997;28:185–198
  152. Bohner H, Tirier C, Rotzcher VM. Indications for and results of splenectomy in different hematologic disorders. Langenbecks Archives of Chirurgie. 1997;382:79–82
  153. Barosi G, Ambrosetti A, Centra A, et al. Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian cooperative study group on myeloid with myeloid metaplasia. Blood. 1998;91:3630–3636
  154. Akpek G, McAneny D, Weintraub L. Risks and benefits of splenectomy in myelofibrosis with myeloid metaplasia: a retrospective analysis of 26 cases. Journal of Surgical Oncology. 2001;77:42–48
  155. Silverstein MN. Control of hypersplenism and painful splenomegaly in myeloid metaplasia by irradiation. International Journal of Radiation Oncology, Biology, Physics. 1977;2:1221–1222
  156. Greenberger JS, Chaffey JT, Rosenthal DS, Moloney WC. Irradiation for control of hypersplenism and painful splenomegaly in myeloid metaplasia. International Journal of Radiation Oncology, Biology, Physics. 1977;2:1083–1090
  157. Slanina J, Vondraczek A, Wannenmacher M. Symptomatic irradiation therapy of the spleen in advanced osteomyelosclerosis. Deutsche Medizinische Wochenschrift. 1986;111:1144–1150
  158. Wagner H, McKeough PG, Desforges J, Madoc-Jones H. Splenic irradiation in the treatment of patients with chronic myelogenous leukemia or myelofibrosis with myeloid metaplasia. Results of daily and intermittent fractionation with and without concomitant hydroxyurea. Cancer. 1986;58:1204–1207
  159. Bouabdallah R, Coso D, Gonzague-Casabianca L, et al. Safety and efficacy of splenic irradiation in the treatment of patients with idiopathic myelofibrosis: a report on 15 patients. Leukemia Research. 2000;24:491–495
  160. Leinweber C, Order SE, Calkins AR. Whole-abdominal irradiation for the management of gastrointestinal and abdominal manifestations of agnogenic myeloid metaplasia. Cancer. 1991;68:1251–1254
  161. Koch C, Li C, Mesa R, Tefferi A. Nonhepatosplenic extrameduallry hematopoiesis: associated diseases, pathology, clinical course, and treatment. Mayo Clinic Proceedings. 2003;78:1223–1233
  162. Weinschenker P, Kutner JM, Salvajoli JV, et al. Whole-pulmonary low-dose radiation therapy in agnogenic myeloid metaplasia with diffuse lung involvement. American Journal of Hematology. 2002;69:277–280

PII: S1521-6926(05)00095-2

doi: 10.1016/j.beha.2005.07.008

Best Practice & Research Clinical Haematology
Volume 19, Issue 3 , Pages 495-517 , September 2006

Article Tools